1. Home
  2. SNDX vs NNE Comparison

SNDX vs NNE Comparison

Compare SNDX & NNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • NNE
  • Stock Information
  • Founded
  • SNDX 2005
  • NNE 2022
  • Country
  • SNDX United States
  • NNE United States
  • Employees
  • SNDX N/A
  • NNE N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • NNE
  • Sector
  • SNDX Health Care
  • NNE
  • Exchange
  • SNDX Nasdaq
  • NNE NYSE
  • Market Cap
  • SNDX 1.1B
  • NNE 1.2B
  • IPO Year
  • SNDX 2016
  • NNE 2024
  • Fundamental
  • Price
  • SNDX $9.48
  • NNE $37.31
  • Analyst Decision
  • SNDX Strong Buy
  • NNE Strong Buy
  • Analyst Count
  • SNDX 11
  • NNE 2
  • Target Price
  • SNDX $35.91
  • NNE $58.00
  • AVG Volume (30 Days)
  • SNDX 1.8M
  • NNE 5.5M
  • Earning Date
  • SNDX 07-31-2025
  • NNE 08-13-2025
  • Dividend Yield
  • SNDX N/A
  • NNE N/A
  • EPS Growth
  • SNDX N/A
  • NNE N/A
  • EPS
  • SNDX N/A
  • NNE N/A
  • Revenue
  • SNDX $43,722,000.00
  • NNE N/A
  • Revenue This Year
  • SNDX $426.77
  • NNE N/A
  • Revenue Next Year
  • SNDX $98.31
  • NNE N/A
  • P/E Ratio
  • SNDX N/A
  • NNE N/A
  • Revenue Growth
  • SNDX N/A
  • NNE N/A
  • 52 Week Low
  • SNDX $8.58
  • NNE $6.30
  • 52 Week High
  • SNDX $25.07
  • NNE $48.05
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 36.85
  • NNE N/A
  • Support Level
  • SNDX $11.00
  • NNE N/A
  • Resistance Level
  • SNDX $11.83
  • NNE N/A
  • Average True Range (ATR)
  • SNDX 0.58
  • NNE 0.00
  • MACD
  • SNDX -0.11
  • NNE 0.00
  • Stochastic Oscillator
  • SNDX 10.31
  • NNE 0.00

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About NNE NANO NUCLEAR ENERGY INC

Nano Nuclear Energy Inc is an early-stage nuclear energy company developing smaller, cheaper, and safer portable clean energy solutions. It is focused on four business lines as part of development-Micro Nuclear Reactor Business is developing the next-generation nuclear microreactors, in particular ZEUS, a solid core battery reactor, and ODIN, a low-pressure salt coolant reactor; Fuel Processing Business; Fuel Fabrication Business; Fuel Transportation Business, and Nuclear Consultation Services.

Share on Social Networks: